评估配戴吾度真晰全像差矫正镜片视觉质量和舒适度

注册号:

Registration number:

ChiCTR2500112395 

最近更新日期:

Date of Last Refreshed on:

2025-11-13 15:39:44 

注册时间:

Date of Registration:

2025-11-13 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

评估配戴吾度真晰全像差矫正镜片视觉质量和舒适度

Public title:

A Clinical trial to evaluate the visual quality and comfort of wearing Wudu total aberration correction lenses

注册题目简写:

English Acronym:

研究课题的正式科学名称:

评估配戴吾度真晰全像差矫正镜片视觉质量和舒适度

Scientific title:

A Clinical trial to evaluate the visual quality and comfort of wearing Wudu total aberration correction lenses

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈晓琴 

研究负责人:

李丽华 

Applicant:

Chen Xiaoqin 

Study leader:

Li Lihua 

申请注册联系人电话:

Applicant telephone:

+86 22 2721 7663

研究负责人电话:

Study leader's
telephone:

+86 22 2721 7663

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

chenxq017@163.com

研究负责人电子邮件:

Study leader's E-mail:

tysgzxlccs@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市和平区甘肃路4号

研究负责人通讯地址:

天津市和平区甘肃路4号

Applicant address:

No. 4, Gansu Road, Heping District, Tianjin City

Study leader's address:

No. 4, Gansu Road, Heping District, Tianjin City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津市眼科医院

Applicant's institution:

Tianjin Eye Hospital

研究负责人所在单位:

天津市眼科医院

Affiliation of the Leader:

Tianjin Eye Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2025042

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津市眼科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committees of Tianjin Eye Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-08-26 00:00:00

伦理委员会联系人:

郭雅图

Contact Name of the ethic committee:

Guo Yatu

伦理委员会联系地址:

天津市和平区甘肃路4号

Contact Address of the ethic committee:

No. 4, Gansu Road, Heping District, Tianjin City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 22 2731 3336

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津市眼科医院

Primary sponsor:

Tianjin Eye Hospital

研究实施负责(组长)单位地址:

天津市和平区甘肃路4号

Primary sponsor's address:

No. 4, Gansu Road, Heping District, Tianjin City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市眼科医院

具体地址:

天津市和平区甘肃路4号

Institution
hospital:

Tianjin Eye Hospital

Address:

No. 4, Gansu Road, Heping District, Tianjin City

经费或物资来源:

由申办者浙江爱至瞳医疗科技有限公司提供

Source(s) of funding:

Provided by Aizhitong (Zhejiang) Medical Technology Co.,Ltd

研究疾病:

屈光不正  

Target disease:

Refractive error

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机交叉对照 

Study design:

Cross-over 

研究目的:

通过与对照组比较,评估配戴0.05D间隔全像差个性化矫正镜片的视觉质量和舒适度。  

Objectives of Study:

The visual quality and comfort of wearing 0.05D interval total aberration personalized correction lenses were evaluated by comparison with the control group.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.有过眼外伤或眼内手术史者; 2.临床上有意义的裂隙灯检查发现; 3.眼底检查结果>=2级; 4.眼压异常(眼压<10mmHg或眼压>21mmHg或双眼眼压差≥5mmHg); 5.合并有其他眼部疾病,如葡萄膜炎等各种炎症、青光眼、白内障、眼底病、眼部肿瘤、眼外伤、显性斜视患者;以及任何影响视功能的眼部病变; 6.患有全身性疾病造成免疫低下的患者,如急、慢性鼻窦炎,糖尿病,唐氏综合症,类风湿性关节炎,精神病患者或其他研究者认为不适合配戴框架眼镜等疾病; 7.3个月内参加过药物临床试验或使用过硬性接触镜者; 8.只有单眼符合入选标准者; 9.不能按照试验要求定期进行随访者; 10.配戴像差试戴片感受无提升者; 11.研究者判定不能入选者

Exclusion criteria:

1. Those who have a history of ocular trauma or intraocular surgery; 2. Clinically significant slit lamp examination findings; 3. The result of the fundus examination is grade 2 or above; 4. Abnormal intraocular pressure (intraocular pressure < 10mmHg or > 21mmHg or intraocular pressure difference between both eyes ≥5mmHg); 5. Patients with other ocular diseases, such as uveitis and various other inflammations, glaucoma, cataracts, retinal diseases, ocular tumors, ocular trauma, and overt strabismus; And any ocular lesions that affect visual function; 6. Patients with systemic diseases that cause weakened immunity, such as acute or chronic sinusitis, diabetes, Down syndrome, rheumatoid arthritis, mental patients, or other diseases that researchers consider unsuitable for wearing frame glasses, etc. 3. Those who have participated in drug clinical trials or used rigid contact lenses within 3 months; 8. Only one eye meets the inclusion criteria; 9. Those who fail to follow up regularly as required by the test; 10. Those who do not experience any improvement when wearing aberration try-on lenses; 11. The researchers determined that the candidates could not be selected

研究实施时间:

Study execute time:

From 2025-10-15 00:00:00 To 2026-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-10-15 00:00:00 To 2025-12-15 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

20

Group:

Experimental Group

Sample size:

干预措施:

配戴0.05D间隔全像差个性化矫正镜片,经历两周洗脱期后,配戴0.05D间隔单光镜片

干预措施代码:

Intervention:

After wearing 0.05-day interval total aberration personalized correction lenses and going through a two-week elution period, 0.05-day interval single vision lenses were worn

Intervention code:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

配戴0.05D间隔单光镜片,经历两周洗脱期后,配戴0.05D间隔全像差个性化矫正镜片

干预措施代码:

Intervention:

Single-vision lenses with 0.05D intervals were worn. After a two-week elution period, total aberration personalized correction lenses with 0.05D intervals were worn

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市眼科医院 

单位级别:

三甲 

Institution
hospital:

Tianjin Eye Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

斯特列尔比

指标类型:

主要指标

Outcome:

Strehl Ratio

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主观感受评分

指标类型:

次要指标

Outcome:

Subjective feeling score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

远近高低对比度视力

指标类型:

次要指标

Outcome:

high and low contrast visual acuity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机化区组设计的方法对纳入的研究对象进行随机分配。研究对象入组后将给予相应的随机号和随机分配方案。一旦随机号已经使用,即使病例脱落,此随机号和相应的分配方案不再使用,但研究病历调查内容应保存。

Randomization Procedure (please state who generates the random number sequence and by what method):

A randomized block group design is used to randomly assign the included study subjects. Study subjects will be given the appropriate randomisation number and random allocation scheme upon enrolment. Once the randomisation number has been used, this randomisation number and the corresponding allocation scheme will no longer be used even if the case is dislodged, but the contents of the study medical record survey should be preserved.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,对研究参与者和研究者设盲

Blinding:

Double-blind, blinding both the research participants and the researchers

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后,通过ResMan(www.medresman.org.cn)方式共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the end of the study, it was shared by ResMan (www.medresman.org.cn).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF;EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-11-13 15:39:40